share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  09/09 11:15

Moomoo AI 已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on September 9, 2024. The program, which began on August 7, 2024, is part of a larger 12-month share repurchase plan initiated on February 6, 2024, with a total budget of up to DKK 20 billion. As of September 6, 2024, Novo Nordisk has repurchased 12,023,313 B shares at an average price of DKK 880.98 per share, amounting to DKK 10,592,256,521. The current phase of the program aims to repurchase B shares for up to DKK 2.4 billion between August 7 and November 4, 2024. Since the last announcement, 956,187 B shares have been acquired for a total of DKK 864,550,471. Novo Nordisk now holds 13,351,944 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on September 9, 2024. The program, which began on August 7, 2024, is part of a larger 12-month share repurchase plan initiated on February 6, 2024, with a total budget of up to DKK 20 billion. As of September 6, 2024, Novo Nordisk has repurchased 12,023,313 B shares at an average price of DKK 880.98 per share, amounting to DKK 10,592,256,521. The current phase of the program aims to repurchase B shares for up to DKK 2.4 billion between August 7 and November 4, 2024. Since the last announcement, 956,187 B shares have been acquired for a total of DKK 864,550,471. Novo Nordisk now holds 13,351,944 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
全球領先的醫療保健公司諾和諾德(Novo Nordisk A/S)於2024年9月9日宣佈了其股票回購計劃的進展。該計劃於2024年8月7日開始,是2024年2月6日啓動的較大規模的爲期12個月的股票回購計劃的一部分,總預算高達200億丹麥克朗(DKK)。截至2024年9月6日,諾和諾德已以平均每股880.98丹麥克朗的價格回購了120233130億股,總計金額爲105,922,565,521丹麥克朗。當前階段的計劃旨在於2024年8月7日至11月4日回購多達24億丹麥克朗的b股。自上次公告以來,已獲得了9561870億股,總計金額爲864,550,471丹麥克朗。諾和諾德目前持有133519440億股作爲庫存股,佔股本的0.3%。該公司的股票在納斯達克哥本哈根交易,其ADR在紐約證券交易所交易。
全球領先的醫療保健公司諾和諾德(Novo Nordisk A/S)於2024年9月9日宣佈了其股票回購計劃的進展。該計劃於2024年8月7日開始,是2024年2月6日啓動的較大規模的爲期12個月的股票回購計劃的一部分,總預算高達200億丹麥克朗(DKK)。截至2024年9月6日,諾和諾德已以平均每股880.98丹麥克朗的價格回購了120233130億股,總計金額爲105,922,565,521丹麥克朗。當前階段的計劃旨在於2024年8月7日至11月4日回購多達24億丹麥克朗的b股。自上次公告以來,已獲得了9561870億股,總計金額爲864,550,471丹麥克朗。諾和諾德目前持有133519440億股作爲庫存股,佔股本的0.3%。該公司的股票在納斯達克哥本哈根交易,其ADR在紐約證券交易所交易。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息